UAE: "Chinese Sinopharm COVID-19 Vaccine 86% Effective"

[Asia Economy Reporter Koo Chae-eun] The United Arab Emirates (UAE) Ministry of Health and Prevention announced on the 9th that the Sinopharm (China National Pharmaceutical Group) COVID-19 vaccine showed 86% efficacy in Phase 3 clinical trials.

The UAE Ministry of Health and Prevention explained, "The seroconversion rate of neutralizing antibodies reached 99%, and the prevention effect for mild and severe cases was 100%, according to the analysis results. This indicates no serious safety concerns."

Since late June, the UAE has been conducting clinical trials administering Sinopharm's inactivated vaccine candidate to over 31,000 people from 125 countries residing domestically. Subsequently, in September, the UAE became the first country in the world to approve limited emergency use of the Sinopharm vaccine.

However, it did not disclose whether any side effects occurred among the vaccine trial recipients. Sinopharm is also conducting Phase 3 clinical trials in Egypt, Jordan, and Bahrain.

This content was produced with the assistance of AI translation services.